Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Geron Corp | GERN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.73 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.73 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.64 - 4.05 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.73 | USD |
Geron Corp Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.03B | 546.06M | - | 237k | -184.13M | -0.34 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Geron News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GERN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.80 | 4.05 | 3.40 | 3.62 | 12,019,248 | -0.07 | -1.84% |
| 1 Month | 3.31 | 4.05 | 3.05 | 3.43 | 10,570,260 | 0.42 | 12.69% |
| 3 Months | 2.16 | 4.05 | 1.64 | 2.69 | 13,173,227 | 1.57 | 72.69% |
| 6 Months | 1.76 | 4.05 | 1.64 | 2.48 | 8,912,622 | 1.97 | 111.93% |
| 1 Year | 2.06 | 4.05 | 1.64 | 2.58 | 7,412,527 | 1.67 | 81.07% |
| 3 Years | 1.45 | 4.05 | 0.9899 | 2.30 | 5,323,180 | 2.28 | 157.24% |
| 5 Years | 1.79 | 4.05 | 0.75 | 2.16 | 4,133,439 | 1.94 | 108.38% |
Geron Description
| Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. |
